- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (BNTX)
122.68
+2.88(+2.40%)
Closed
After Hours
122.00-0.68(-0.55%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.68
124.14
52 wk Range
76.53
131.49
BNTX Scorecard
Full Analysis
Management has been aggressively buying back shares
This is the main Biontech stock price chart and current quotes. You can find more details about BNTX stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.68124.14
52 wk Range
76.53131.49
UnlockBNTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
111.43
Downside
-9.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - BioNTech unveils AI advancements in immunotherapy
- Investing.com
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - BioNTech unveils AI advancements in immunotherapy
- Investing.com
InvestingPro Research for BioNTech SE
Financial Outlook | Analyst price targets range from $100 to $122, reflecting BioNTech's transition from COVID-19 vaccine focus to its diverse oncology portfolio |
Strategic Partnerships | Delve into BioNTech's collaborations, including the potential of acasunlimab in NSCLC treatment and the anticipated PM8002 presentation |
Vaccine Innovation | Explore BioNTech's personalized neoantigen-targeted mRNA-based cancer vaccines, demonstrating long-term benefits in pancreatic cancer patients |
Oncology Advances | BioNTech's oncology pipeline shows promise, with BNT327 achieving significant efficacy in solid tumors and impressive response rates in TNBC patients |
BioNTech SE Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa’s mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Compare BNTX to Peers and Sector
Metrics to compare | BNTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −52.7x | −2.0x | −0.6x | |
PEG Ratio | 0.47 | 0.00 | 0.00 | |
Price / Book | 1.4x | 1.6x | 2.6x | |
Price / LTM Sales | 9.9x | 4.6x | 3.2x | |
Upside (Analyst Target) | −0.2% | 92.1% | 41.1% | |
Fair Value Upside | Unlock | 20.4% | 5.9% | Unlock |
People Also Watch
FAQ
What Is the BioNTech (BNTX) Stock Price Today?
The BioNTech stock price today is 122.68
What Stock Exchange Does BioNTech Trade On?
BioNTech is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for BioNTech?
The stock symbol for BioNTech is "BNTX."
Does BioNTech Pay Dividends? What’s The Current Dividend Yield?
The dividend yield is 1.44%.
What Is the BioNTech Market Cap?
As of today, BioNTech market cap is 29.17B.
What is BioNTech Earnings Per Share?
The BioNTech EPS is -2.10.
What Is the Next BioNTech Earnings Date?
BioNTech will release its next earnings report on Nov 04, 2024.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.